Attapon Cheepsattayakorn^1,2*, Ruangrong Cheepsattayakorn³ and Porntep Siriwanarangsun¹

¹Faculty of Medicine, Western University, Pathumtani Province, Thailand
²10^thZonal Tuberculosis and Chest Disease Center, Chiang Mai, Thailand
³Department of Pathology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand

*Corresponding Author: Attapon Cheepsattayakorn, 10^th Zonal Tuberculosis and Chest Disease Center, Chiang Mai, Thailand.

Received: August 27, 2021 ; Published: September 08, 2021

  In patients with cancer, SARS-CoV-2 (COVID-19) can contribute to increasing morbidity and mortality [1-3] and decreased survival was found in patients with hematological and intrathoracic malignancies, poor performance status, comorbidities, and increased age [3-5]. Patients with hematological malignancies who were treated with stem cell transplantation and anti-CD-20 antibody demonstrated lower rates of seroconversion, compared to COVID-19-infected-cancer patients [6,7]. Patients with hematological malignancies might have substantially compromised B-cell and T-cell responses [8]. These study results indicated that following COVID-19 vaccination, overall high seroconversion rates could be anticipated in cancer patients due to different mechanisms and degrees of immune suppression, such as cell therapies (particularly chimeric antigen receptor (CAR)-T cell), anti-CD-20 antibody (B-cell depleting) therapies, stem cell transplantation, immunosuppressive effects of corticosteroid treatment, and cytotoxic-chemotherapy-bone-marrow-suppressive effects in certain subgroups of cancer patients [9]. Currently, there are lacking data in cancer patients in protection following SARS-CoV-2 (COVID-19) infection, reinfection by various SARS-CoV-2 (COVID-19) variants, or COVID-19 vaccination although mucosal surface antigens (e.g. IgA and protective T-cell responses) might be similarly important in protection from natural SARS-CoV-2 (COVID-19) infection [10]. The association of carcinogenesis with genomic information encoding vaccines, particularly with very-transient-intracellular-presence-COVID-19-mRNA vaccines is likely very low [11].

References

1. Bakouny Z., et al. “CD8+ T cells contribute to survival in patients with COVID-19 and cancer: current challenges and perspectives”. Cancer Cell 38 (2020): 629-646.
2. Kuderer NM., et al. “Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study”. Lancet 395 (2020): 1907-1918.
3. Mehta V., et al. “Case fatality rate of cancer patients with COVID-19 in a New York hospital system”. Cancer Discovery 10 (2020): 935-941.
4. Grivas P., et al. “Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium”. Annals of Oncology 32 (2021): 787-800.
5. Robilotti EV., et al. “Determinants of COVID-19 disease severity in patients with cancer”. Nature Medicine 26 (2020): 1218-1223.
6. Marra A., et al. “Seroconversion in patients with cancer and oncology health care workers infected by SARS-CoV-2”. Annals of Oncology 32 (2020): 113-119.
7. Thakkar A., et al. “Patterns of seroconversion for SARS-CoV-2 IgG in patients with malignant disease and association with anticancer therapy”. Nature Cancer 2 (2021): 392-399.
8. Chamilos G., et al. “Are all patients with cancer at heightened risk for severe coronavirus disease 2019 (COVID-19)?” Clinical Infectious Disease2 (2021): 351-356.
9. Thakkar A., et al. “Seroconversion rates following COVID-19 vaccination among patients with cancer”. Cancer Cell 39 (2021): 1-10.
10. Korompoki E., et al. “COVID-19 vaccines in patients with cancer-a welcome addition, but there is need for optimization”. JAMA Oncology (2021): E1-E2.
11. Górecki DC and Simons JP. “The dangers of DNA vaccination”. Nature Medicine2 (1999): 126.
12. Kang CK., et al. “Cell-mediated immunogenicity of influenza vaccination in patients with cancer receiving immune checkpoint inhibitors”. Journal of Infectious Disease11 (2020): 1902-1909.
13. Fanciullino R., et al. “COVID-19 vaccine race: watch your step for cancer patients”. British Journal of Cancer5 (2021): 860-861.
14. Desai A., et al. “COVID-19 vaccine guidance for patients with cancer participating in oncology Clinical Trials”. Nature Reviews Clinical Oncology 18 (2021): 313-319.
15. Waissengrin B., et al. “Short-term safety on the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors”. Lancet Oncology 22 (2021): 581-583.
16. Friese CR., et al. “Care without a compass: including patients with cancer in COVID-19 studies”. Cancer Cell (2021).
17. Hwang JK., et al. “COVID-19 vaccines for patients with cancer : benefit likely outweigh risks”. Journal of Hematology and Oncology 14 (2021): 38.

Citation

Citation: Attapon Cheepsattayakorn.,et al. “COVID-19 Vaccination in Cancer Patients”. Acta Scientific Microbiology 4.10 (2021): 21-22.

Copyright

Copyright: © 2021 Attapon Cheepsattayakorn.,et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.